HPV vaccination alongside surgical treatment for cervicallesions may reduce risk of further disease bmj_latest
To explore this further, researchers analyzed the results of 18 studies to assess the effect of HPV vaccination on risk of HPV infection or recurrence of lesions related to HPV infection after local surgical treatment.
The results show that the risk of recurrence of high grade preinvasive disease was reduced by 57% in individuals who were vaccinated compared with those who were not vaccinated. The risk of recurrence of higher grade CIN3 was also reduced in patients who were vaccinated but again, there was a high level of uncertainty about the quality of this evidence.
What's more, average age of participants was not provided in most studies, and factors such as smoking were not controlled for in many studies.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial | Journal of Clinical OncologyPURPOSE To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to 2 years of goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 mg orally once daily), combined goserelin and tamoxifen, or no adjuvant endocrine therapy (control) is performed. Random assignment was stratified by lymph node status; lymph node–positive patients (n=459) were allocated to standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil). Primary tumor immunohistochemistry (n=731) and gene expression profiling (n=586) were conducted in 2020. The 70-gene signature identified genomic low-risk and high-risk patients. Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and multivariable time-varying flexible parametric modeling assessed the long-term distant recurrence-free interval (DRFI). Swedish high-quality registries allowed a complete follow-up of 20 years. RESULTS In estrogen receptor–positive patients (n=584, median age 47 years), goserelin, tamoxifen, and the combination significantly improved long-term distant recurrence-free interval compared with control (multivariable hazard ratio [HR], 0.49; 95% CI, 0.32 to 0.75, HR, 0.57; 95% CI, 0.38 to 0.87, and HR, 0.63; 95% CI, 0.42 to 0.94, respectively). Significant goserelin-tamoxifen interaction was observed (P=.016). Genomic low-risk patients (n=305) significantly benefitted from tamoxifen (HR, 0.24; 95% CI, 0.10 to 0.60), and genomic high-risk patients (n=158) from goserelin (HR, 0.24; 95% CI, 0.10 to 0.54). Increased risk from the addition of tamoxifen to goserelin was seen in genomic high-risk patients (HR, 3.36; 95% CI, 1.39 to 8.07). Moreover, long-lasting 20-year tamoxifen benefit was seen in genomic low-risk patients, whereas genomic high-risk patients had early goserelin benefit. CONCLUSION This study shows 20-year benefi
Read more »
Reduced severity of COVID-19 in pregnant women during the Omicron waveA new study assesses the clinical outcomes of COVID-19 in pregnant women to determine whether Omicron and vaccination status impacted disease severity.
Read more »
Further SARS-CoV-2 variants, and intermittent epidemics may become the 'new normal'Further SARS-CoV-2 variants, and intermittent epidemics may become the 'new normal' Coronavirus Disease COVID Omicron VOCs Variants SARSCoV2 NatureComms TheQuadram imperialcollege UniofOxford
Read more »
What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations?What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations? medrxivpreprint UniofOxford SARSCoV2 COVID19 Vaccination Vaccine Efficacy Booster
Read more »